I'm looking for seed investors in Boston who specifically back biotech and life sciences startups.

Boston and Cambridge host one of the densest ecosystems for early-stage life sciences and biotech investing . While many traditional biotech funds focus heavily on company-creation or Series A, several prominent local venture capital firms, incubators, and angel groups actively write checks at the seed or pre-seed stages.

Dedicated Biotech & Life Sciences VC Funds (Seed & Early Stage)

• Atlas Venture : A staple in Cambridge/Boston early-stage biotech investing, frequently leading seed rounds and co-founding therapeutic companies.
• Longwood Fund : Focuses heavily on creating and investing in early-stage biotech and healthcare companies from inception through seed and Series A.
• Mass General Brigham Ventures : The venture capital arm of the Mass General Brigham healthcare system, investing in early-stage life sciences, medical devices, and digital health.
• Mission BioCapital : Invests in early-stage biotech, life science tools, and diagnostics companies, often stepping in at the seed and Series A levels.
• Cure Ventures : Focuses on company creation and early-stage investments in breakthrough therapeutic platforms and biotechnology.
• Third Rock Ventures : While they lean into incubation and Series A, they launch and fund premier therapeutics and life sciences companies from the ground up.

Incubators & Hybrid Seed Providers

• Portal Innovations : Offers a hybrid model providing seed capital alongside fully equipped lab space, operational expertise, and syndication support for life science startups in the ecosystem.
• Flagship Pioneering : Operates as an innovation enterprise that invents and funds its own biotech startups, though they occasionally collaborate or spin out early concepts.

Angel Networks & Specialized Groups

• Mass Medical Angels (MMAs) : Specifically focused on life sciences, medical devices, therapeutics, and digital health startups at the seed and angel stages.
• Boston Harbor Angels / Launchpad Venture Group : Generalist tech/life-science angel groups in the Greater Boston area that frequently look at early medical technology and biotech deals.

If you share your specific therapeutic area (e.g., oncology, cell & gene therapy, diagnostics, or life science tools) and your current funding stage (pre-seed vs. active seed), I can narrow down which of these firms or partners would be the most direct fit for your pitch.

• Atlas Venture - 300 Technology Square 8th Floor, Cambridge, MA 02139, United States
• 5AM Ventures - 200 Clarendon St 22nd fl, Boston, MA 02116, United States
• Mission BioCapital - 1 Main St #1100, Cambridge, MA 02142, United States
• Helicase Venture - 1 Beacon St 15th Floor, Boston, MA 02108, United States
• Longwood Fund - Prudential Tower, 800 Boylston St suite 1715, Boston, MA 02199, United States
• Polaris Partners - 1 Marina Park Drive, Boston, MA 02210, United States
• Third Rock Ventures - 201 Brookline Ave, Boston, MA 02215, United States
• Flagship Pioneering - 55 Cambridge Pkwy Ste 800E, Cambridge, MA 02142, United States
• Northpond Ventures - 4 Brattle St, Cambridge, MA 02138, United States
• Xontogeny - 361 Newbury St Ste 501, Boston, MA 02115, United States
• MP Healthcare Venture Management Inc - 33 Arch St, Boston, MA 02110, United States
• Newpath Partners - 800 Boylston St Suite 2222, Boston, MA 02199, United States
• Excel Venture Management - 200 Clarendon St 17th Floor, Boston, MA 02116, United States
• Delos Capital - 201 Broadway Ste 330, Cambridge, MA 02139, United States
• SV Health Investors - 28 State St Ste 980, Boston, MA 02109, United States
• Qiming Venture Partners - 139 Main St Ste 100, Cambridge, MA 02142, United States

If you mean true seed/pre-seed investors rather than firms that mostly enter at Series B+, Boston/Cambridge has a particularly strong biotech bench. I’d prioritize these:

Best targets for a biotech seed round

• Atlas Venture — Top-tier target. Cambridge-based and explicitly seed-led; Atlas says its model is to identify promising science and build/seed biotech companies, often alongside entrepreneurs-in-residence.
• 5AM Ventures — Specialist life-sciences VC with a Boston presence and a strong early-stage orientation. Particularly relevant for therapeutics and platform biotech.
• Mission BioCapital — Excellent for very early biotech. Its Platinum Program provides pre-seed funding and lab space, making it especially interesting for founders coming out of academia or with an early scientific program.
• Helicase Venture — Boston early-stage specialist focused on life sciences and Bio-IT, explicitly investing at seed and Series A, with typical initial investments of $1M–$5M.
• Longwood Fund — Boston life-sciences investor with a company-creation orientation and emphasis on early-stage opportunities.
• Polaris Partners — Long-established Boston investor in healthcare, biotech and life sciences; worth targeting if you're beyond the earliest concept stage or have a particularly strong platform/therapeutic thesis.
• Third Rock Ventures — Especially interesting if you're building a company around breakthrough therapeutic science rather than simply seeking a conventional seed check. Third Rock is known for company creation and hands-on involvement from early concepts onward.
• Flagship Pioneering — Cambridge-based venture-creation powerhouse. It can be a major target for transformative biotech/platform science, although its model is more company creation/incubation than a conventional seed VC.

Also worth putting on the list

• Northpond Ventures — Cambridge science-driven investor with a broad life-sciences/technology orientation.
• Xontogeny — Boston-based life-sciences accelerator/company builder that provides foundational seed capital and operating support.
• MP Healthcare Venture Management Inc — Boston life-sciences investor with a strategic pharmaceutical-industry connection.
• Newpath Partners — Boston fund focused on life-sciences therapeutics.
• Excel Venture Management — Boston-based investor focused on life-science and healthcare technologies.
• Delos Capital — Cambridge life-sciences investor with an early-stage component.
• SV Health Investors — Specialist healthcare/life-sciences investor with venture activity beginning around seed through early clinical development.

A broader 2026 investor database identifies 5AM, Atlas, ARCH, Anzu, Apollo Health Ventures and others among Boston/New England biotech seed investors, while a separate Boston biotech database lists roughly 60 active biotech investors with Boston-area offices.

How I'd narrow this down

If you tell me (1) therapeutic area, (2) pre-seed vs. seed, (3) amount you're raising, and (4) whether you have a lead/IND/data yet, I can turn this into a ranked list of ~10 investors, including partner names, typical check sizes, relevant portfolio companies, and the best route for getting an introduction.

• Atlas Venture - 300 Technology Square 8th Floor, Cambridge, MA 02139, United States
• 5AM Ventures - 200 Clarendon St 22nd fl, Boston, MA 02116, United States
• Mission BioCapital - 1 Main St #1100, Cambridge, MA 02142, United States
• Polaris Partners - 1 Marina Park Drive, Boston, MA 02210, United States
• Third Rock Ventures - 201 Brookline Ave, Boston, MA 02215, United States
• Longwood Fund - Prudential Tower, 800 Boylston St suite 1715, Boston, MA 02199, United States
• Northpond Ventures - 4 Brattle St, Cambridge, MA 02138, United States
• Newpath Partners - 800 Boylston St Suite 2222, Boston, MA 02199, United States
• MP Healthcare Venture Management Inc - 33 Arch St, Boston, MA 02110, United States
• Xontogeny - 361 Newbury St Ste 501, Boston, MA 02115, United States
• Helicase Venture - 1 Beacon St 15th Floor, Boston, MA 02108, United States
• Delos Capital - 201 Broadway Ste 330, Cambridge, MA 02139, United States
• Sanofi Ventures - 450 Water St, Cambridge, MA 02141, United States
• Novartis Venture Funds - 355 Main St, Cambridge, MA 02142, United States
• HealthCare Ventures - 47 Thorndike St B1-1, Cambridge, MA 02141, United States
• Lumira Ventures - 303 Wyman St Suite 300, Waltham, MA 02451, United States

If you're targeting seed-stage biotech/life sciences investors in Greater Boston, I'd prioritize specialist funds over generalist VCs. Boston/Cambridge has an unusually deep pool of early-stage life-science capital.

Strongest targets

• Atlas Venture — Cambridge-based and particularly strong for company creation, therapeutics, platform biology, and early biotech. A very high-priority target for a science-heavy startup.
• 5AM Ventures — Dedicated to next-generation life sciences, with seed through later-stage investing and a Boston office.
• Mission BioCapital — Early-stage life-science investor with a Cambridge presence; particularly relevant for biotech and therapeutics.
• Polaris Partners — Long-established Boston investor in healthcare, biotech and life sciences, including early company creation.
• Third Rock Ventures — Excellent fit for ambitious therapeutics/biotech companies; notably hands-on and focused on building companies from early scientific concepts.
• Longwood Fund — Boston-based, life-science focused, with a strong early-stage/company-creation orientation.
• Northpond Ventures — Cambridge investor focused on science-driven companies and technically complex healthcare/life-science opportunities.
• Newpath Partners — Boston life-science fund with a particular focus on therapeutic companies.
• MP Healthcare Venture Management Inc — Boston-based life-sciences investor; potentially attractive if you want a strategic partner alongside capital.
• Xontogeny — Especially interesting at the seed/foundational stage: it provides seed capital and helps scientific founders turn early innovations into venture-backed companies.
• Helicase Venture — Early-stage Boston investor focused on healthcare/life sciences, including biotech, therapeutics, synthetic biology and Bio-IT.
• Delos Capital — Cambridge life-sciences investor spanning early-stage through growth opportunities.

Also worth considering

For corporate/strategic capital, Sanofi Ventures and Novartis Venture Funds are relevant Cambridge-based options. They're somewhat different from traditional seed VCs because of their pharmaceutical affiliations.

For a very early company, Iaso Ventures is another one to investigate: its published investment profile includes biotech, therapeutics, pharmaceuticals and pre-seed/seed investing, with a Boston focus.

How I'd narrow this down

If you tell me (1) your biotech subtype (therapeutics, diagnostics, medtech, synthetic biology, AI drug discovery, etc.), (2) current stage (pre-seed/seed/Series A), and (3) how much you're raising, I can turn this into a ranked top-10 target list with relevant partners, typical check sizes, portfolio companies, and links to each firm's official site.

Boston and Cambridge form the global epicentre for biotechnology and life sciences innovation , meaning there is a deep bench of specialized venture capital firms that focus specifically on company creation, incubation, and seed/pre-seed funding in this space.

A targeted list of prominent Boston-based seed and early-stage life sciences investors includes the following key players:

• Mission BioCapital (Cambridge, MA)
  • Focus: Early-stage biotech, novel therapeutics, medtech, and diagnostics.
  • What they do: Known for active company creation and their dedicated seed/pre-seed initiatives (such as the Platinum Program ), which offer seed funding paired with turnkey lab bench space. Learn more via Mission BioCapital.
• Longwood Fund (Boston, MA)
  • Focus: Science-driven healthcare, biotechnology, pharmaceuticals, and medical devices.
  • What they do: They operate heavily as active co-founders, working hand-in-hand with academic researchers and entrepreneurs to translate early discoveries into clinical-stage therapies, often stepping in operationally at the seed stage. Check details on Longwood Fund.
• Atlas Venture (Cambridge, MA)
  • Focus: Therapeutics and early-stage life sciences.
  • What they do: A premier seed-to-A investor in the Boston ecosystem that builds companies from the ground up, incubating concepts alongside exceptional scientific founders.
• Flagship Pioneering (Cambridge, MA)
  • Focus: Pioneering biotech and breakthrough life sciences platform creation.
  • What they do: While they primarily practice an internal "company-creation" model (inventing ideas themselves rather than funding external pitches), they are the ultimate source of early foundational capital for radical biotech concepts in the area.
• Mass General Brigham Ventures (MGBV) (Somerville/Boston, MA)
  • Focus: Healthcare, medical devices, diagnostics, and therapeutics stemming from clinical and translational research.
  • What they do: As the venture arm of the Mass General Brigham health system, they specialize in early-stage investments that bridge academic medical research and commercial viability.
• Portal Innovations (Boston hub presence)
  • Focus: Life sciences, therapeutics, and medical tech.
  • What they do: A hybrid venture capital firm and incubator model that provides seed capital alongside fully equipped lab space and strategic industry introductions. Explore resources via Portal Innovations.

If you share details on your therapeutic modality (e.g., cell/gene therapy, small molecule, AI-driven drug discovery) and your current stage (academic spinout vs. pre-clinical data ready), I can help narrow down which of these firms is the best cultural and strategic fit for an initial outreach.

Boston and Cambridge (centered around Kendall Square) form the densest life sciences and biotech ecosystem in the world . Seed investing here often blends traditional venture capital with active company-creation models.

Top-tier seed and early-stage investors in the Boston area focusing on biotech and life sciences include:

• Atlas Venture — A premier Cambridge-based early-stage venture firm that focuses heavily on seeding and building breakthrough biotech, therapeutics, and diagnostics companies in close partnership with founding teams.
• Curie.Bio — Operating a specialized seed-funding model explicitly built for therapeutics founders, writing substantial initial checks ($5M to $15M) to help take new concepts through preclinical milestones and development candidates.
• Flagship Pioneering — Headquartered in Cambridge, they function primarily as a venture creation engine rather than a traditional pitch-to-invest fund, conceiving and internally incubating platform-biotech companies from scratch (famous for founding Moderna).
• RA Capital Management — A prominent life sciences and healthcare investment firm based in Boston that actively participates in and leads early private financing and seed-to-venture stages for innovative therapeutic platforms.
• Mass General Brigham Ventures — The corporate venture capital arm for the Mass General Brigham healthcare system, uniquely positioned to fund early-stage medical innovations, digital health, and translational life sciences originating from clinical research.
• Mission BioCapital — An early-stage venture firm targeting biotech, life science tools, and therapeutics across the Cambridge/Boston corridor, frequently backing companies at their earliest institutional milestones.
• Boston Harbor Angels / Mass Medical Angels — Active local angel networks that regularly evaluate pre-seed and seed-stage life sciences, medical devices, and digital health startups in the New England area.

To help narrow down the right targets, could you tell me:

• What is your core modality or therapeutic area (e.g., cell/gene therapy, small molecule, AI-driven discovery)?
• What stage of development are you currently in (idea/academic spinout vs. active preclinical data)?

If you're targeting seed-stage biotech/life sciences investors in the Boston/Cambridge ecosystem, I'd prioritize these:

There is substantial independent evidence that these aren't merely generic Boston VCs: current investor databases specifically identify firms such as Atlas, 5AM, Mission BioCapital, Polaris, and Third Rock among Boston/New England biotech investors, while seed-focused lists identify investors such as Mission BioCapital and other specialist funds as active at the seed stage.

My shortlist by startup type

If you're developing a novel therapeutic:
Atlas, 5AM, Third Rock, Longwood, Polaris, Mission BioCapital.

If you're very early/pre-seed and coming out of academia:
Mission BioCapital, Atlas, 5AM, Xontogeny, Longwood.

If it's biotech + AI/computational biology:
Helicase, Polaris, Mission BioCapital, Atlas, Northpond.

If it's a platform technology rather than a single drug:
Atlas, 5AM, Mission BioCapital, Polaris, Northpond.

One particularly interesting option is Mission BioCapital: its Cambridge operation has a Platinum Program specifically aimed at very early biotech, including up to $500K in pre-seed capital plus lab space.

Also worth knowing: Massachusetts Life Sciences Center's Impact Catalyst is a 2026 seed-stage, non-dilutive program for Massachusetts life-science startups. It requires the company to have committed investors, so it can be useful as additional capital rather than a substitute for your lead seed investor.

If you tell me (1) your biotech area, (2) whether you're pre-seed or seed, and (3) roughly how much you're raising, I can narrow this to 10–15 investors that are unusually well matched, including relevant partners and recent comparable investments.

The Boston/Cambridge ecosystem is the densest life sciences hub globally . Early-stage and seed funding here often blends traditional venture capital with active company-creation (incubation) models.

The key seed and early-stage biotech/life sciences investors in the Boston area include:

• Atlas Venture (Cambridge/Boston) — Focuses heavily on seed-stage therapeutics, diagnostics, and company formation, working hands-on with founding teams.
• Curie.Bio (Boston) — Operates a specialized seed fund (writing checks typically $5M - $15M) dedicated to taking therapeutics through preclinical milestones to development candidates alongside deep operational support.
• Flagship Pioneering (Cambridge) — Rather than traditional pitching, they primarily conceive, build, and fund life sciences and platform biotech companies internally (the creator of Moderna).
• Third Rock Ventures (Boston) — Focuses on discovery, launch, and seed-to-early-stage building of transformational life science and therapeutics companies with dedicated internal operating teams.
• 5AM Ventures (Boston/San Francisco) — Invests actively at the seed and early stages in next-generation life sciences, therapeutics, and drug delivery platforms.
• RA Capital Management (Boston) — Evidence-based multi-stage investor that funds private seed rounds through commercialization, particularly for tech-enabled or computational drug design and platform biology.
• F-Prime Capital (Cambridge/Boston) — Global venture capital firm with a major dedicated healthcare and life sciences practice investing from early discovery to commercial stages.
• Pillar VC (Boston) — A community-backed pre-seed and seed fund that invests broadly in technical breakthroughs, deep tech, and engineering-driven bio/healthcare innovation in New England.
• The Engine (Cambridge) — MIT-connected tough tech fund that backs early-stage, long-development-cycle science and biotech spinouts requiring specialized lab infrastructure.
• Mission BioCapital (Cambridge/Boston) — Invests in early-stage life sciences, therapeutics, and tools, often leveraging close ties to regional academic medical centers and incubators.

If you can share your therapeutic area, modality (e.g., cell/gene therapy, small molecule, AI drug discovery), and whether you need lab incubator space like LabCentral, I can help narrow down which specific partner fits your exact profile.

Absolutely. For seed-stage biotech/life sciences, Boston/Cambridge is one of the strongest ecosystems in the U.S. I’d prioritize investors that explicitly do seed or company creation, rather than broad healthcare VCs that mostly enter at Series A/B.

My shortlist

If you're truly at pre-seed/seed

I'd start with:

1. Atlas → 2. Mission BioCapital → 3. Xontogeny → 4. MPH → 5. 5AM → 6. Longwood

There's supporting evidence for this ranking: current investor databases identify numerous Boston/New England investors specifically as biotech seed investors, including Atlas, MRL Ventures, Iaso, Digitalis and others.

Iaso Ventures is another particularly interesting target if your company sits at the intersection of biotech and data/AI. It describes itself as investing in "biodigital" innovation and explicitly invites entrepreneurs seeking investment to submit their companies.

One important distinction

If by "seed" you mean $1–3M to get a new biotech from scientific concept → initial proof-of-concept, I'd emphasize Atlas, Mission, Xontogeny and MPH.

If you're raising $5–10M+ with substantial data already in hand, I'd broaden the list toward 5AM, Longwood, Third Rock, Polaris, Newpath and other larger life-sciences funds. A current Boston/New England investor database shows a large pool of biotech seed investors, but the practical fit varies substantially by stage and modality.

If you tell me (a) what you're building—therapeutic, diagnostic, platform, medtech, AI-biotech, etc.—(b) how much you're raising, and (c) whether you have a lead investor yet, I can narrow this to 10–15 highly targeted Boston investors, including the relevant partner at each firm and the best route for an introduction.

If you mean true seed/pre-seed investors—not generalist VCs that occasionally do healthcare—Greater Boston has a particularly strong set of options. I’d prioritize these:

The ones I'd approach first

1. Mission BioCapital — probably one of the cleanest matches if you're genuinely at pre-seed/seed. Its Platinum Program is specifically designed for very early biotech companies, with up to $500K in pre-seed capital plus lab space.

2. Atlas Venture — one of the strongest biotech-specific names in the Boston/Cambridge ecosystem. Atlas explicitly describes its investment approach as seed-led and focuses on building breakthrough biotechnology companies.

3. Mass Medical Angels (MA2) — particularly worth targeting if your raise is roughly $250K–$3M. MA2 says it exclusively invests in life sciences and healthcare and can provide all or part of a round.

4. Xontogeny — unusually attractive for a founder who needs more than money. It provides seed capital plus operational/scientific support and invests across therapeutics, diagnostics and devices.

5. Longwood Fund — particularly compelling for therapeutics. Its team has founded more than 20 biotech companies and positions itself as a company creator as well as an investor.

6. 5AM Ventures — a major life-sciences specialist with a Boston presence; I'd put it high on the list for a scientifically differentiated biotech with a credible path toward a venture-scale therapeutic/platform company.

7. Polaris Partners — more established and broader than some of the seed specialists, but its roots are deeply in healthcare/science and its life-sciences portfolio includes molecules, therapeutics and genomics.

One important distinction

For a drug-development biotech, I'd concentrate your outreach on Mission, Atlas, 5AM, Longwood, Third Rock, Xontogeny and Polaris.

For medtech/diagnostics/lab tools, I'd move Mass Medical Angels, Xontogeny, Northpond and Helicase higher.

For biotech + AI/computational biology, Helicase, Northpond, Pillar and Polaris become more interesting.

Also, don't limit your search to Boston proper: Cambridge/Kendall Square is effectively part of the same investor ecosystem, and several of the strongest biotech funds are there.

If you tell me (1) what the startup does, (2) how much you're raising, and (3) pre-seed vs. seed, I can narrow this to 10–15 highly targeted investors and identify the specific partners at each fund who are most likely to take the meeting.

Boston and Cambridge are home to some of the densest life sciences and biotech venture networks in the world, anchored by institutions like Kendall Square . Prominent early-stage and seed-active biotech investors in the Boston area includeAtlas Venture Atlas Venture, Mass General Brigham Ventures Mass General Brigham Ventures, Mission BioCapital Mission BioCapital , and Polaris Partners Polaris Partners.

Note that a significant portion of early biotech funding in Boston relies on "venture creation" models (where firms build companies internally from academic research) rather than traditional open-pitch seed rounds . However, several dedicated funds and angel groups actively source and evaluate early-stage external science.

Specialized Seed & Early-Stage Biotech VCs in Boston

• Atlas Venture : Focuses heavily on seed-stage therapeutics and life science platforms, often co-founding and incubating companies from inception.
• Mass General Brigham Ventures : The venture arm for the Mass General Brigham healthcare system, investing in early life sciences, medical devices, and digital health.
• Mission BioCapital : Invests in early-stage biotech, life science tools, and diagnostics across the Boston ecosystem.
• Polaris Partners : Invests from seed to late-stage in healthcare, tech, and transformative biotech.
• Longwood Fund : Focuses on creating and investing in novel early-stage therapeutics and biotech companies.
• Cure Ventures : Targets early-stage translational medicine and life sciences innovation.

Local Life Sciences Angel Networks & Resources

• Mass Medical Angels : An angel network specifically focused on life sciences, medical devices, and therapeutics at the seed/early stage.
• LabCentral / Labshares : While physical innovation hubs/incubators rather than direct VCs, basing early science out of spaces like LabCentral in Cambridge or Labshares in Watertown puts you in direct contact with active seed scouts and operators.

If you'd like to narrow this down, please share:

• Your exact therapeutic area or technology type (e.g., therapeutics, platform biology, diagnostics, medical devices)
• Your funding stage and data milestone (e.g., in vitro vs. in vivo proof-of-concept)

I can give you more tailored guidance on which firms or networks match your profile.